Noorwegen - Noors - Statens legemiddelverk

sanofi-aventis norge as (1) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 10000 iu

Noorwegen - Noors - Statens legemiddelverk

sanofi-aventis norge (3) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 12000 iu

Noorwegen - Noors - Statens legemiddelverk

sanofi-aventis norge as (1) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 15000 iu

Noorwegen - Noors - Statens legemiddelverk

sanofi-aventis norge (3) - enoksaparinnatrium - injeksjonsvæske, oppløsning - 30000 iu/3 ml

Noorwegen - Noors - Statens legemiddelverk

baxter medical ab - alanin / arginin / glysin / histidin / isoleucin / leucin / lysinhydroklorid / metionin / fenylalanin / prolin / serin / treonin / tryptofan / tyrosin / valin / natriumklorid / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / natriumlaktatoppløsning - peritonealdialysevæske - 0.951 g/ l / 1.071 g/ l / 0.51 g/ l / 0.714 g/ l / 0.85 g/ l / 1.02 g/ l / 0.955 g/ l / 0.85 g/ l / 0.57 g/ l / 0.595 g/ l / 0.51 g/ l / 0.646 g/ l / 0.27 g/ l / 0.3 g/ l / 1.393 g/ l / 5.38 g/ l / 0.184 g/ l / 0.051 g/ l / 4.48 g/ l

Europese Unie - Noors - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - imipenem monohydrat, cilastatin natrium, relebactam monohydrat - gram-negative bakterielle infeksjoner - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 og 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 og 5. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.

Europese Unie - Noors - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostata neoplasmer - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Europese Unie - Noors - EMA (European Medicines Agency)

ucb pharma ltd - natriumoksybat - cataplexy; narcolepsy - andre nervesystemet narkotika - behandling av narkolepsi med katapleksi hos voksne pasienter.

Noorwegen - Noors - Statens legemiddelverk

viatris as - kaliumsitrat - mikstur, oppløsning - 33 mg k/ ml

Noorwegen - Noors - Statens legemiddelverk

zambon spa - kolistimetatnatrium - pulver til infusjonsvæske, oppløsning - 1 mill ie